Early-Stage Triple-Negative Breast Cancer
MediMix had the privilege of consulting with two experts, Prof Duhoux from Cliniques Universitaires St Luc and Prof Evandro De Azambuja from the Institute Jules Bordet, to provide insights on the current treatment recommendations for early-stage triple-negative breast cancer (TNBC) and the management of immunotherapy toxicities.
Early-stage TNBC is known for its aggressive nature and heterogeneous characteristics. The standard treatment approach typically involves systemic chemotherapy, surgery, and, in some cases, radiation therapy. However, the landscape of TNBC treatment has evolved with the introduction of immunotherapy.
Immunotherapy has shown promising results in the treatment of TNBC. However, the challenge lies in managing immune-related adverse events (irAEs) while ensuring treatment efficacy
Prof Duhoux and Prof Evandro De Azambuja provided their expert opinions on the optimal treatment strategies for early-stage TNBC, considering factors such as tumour characteristics, patient profiles, and the potential benefit of immunotherapy. They discussed the importance of personalized approaches, considering the balance between treatment efficacy and the management of immunotherapy toxicities.
With the educational support of:
